NICE have published their review of TPO-RA and have updated their approval for Romiplostim and Eltrombopag

Romiplostim is recommended as an option for treating chronic immune (idiopathic) thrombocytopenic purpura in adults, only if:

• their condition is refractory to standard active treatments and rescue therapies or
• they have severe disease and a high risk of bleeding that needs frequent courses of rescue therapies. 
  
  Romiplostim is recommended only if the company makes it available with the discount agreed in the patient access scheme.

For more details of the updated recommendation for Romiplostim go to https://www.nice.org.uk/guidance/ta221

Eltrombopag is recommended as an option for treating chronic immune (idiopathic) thrombocytopenic purpura in adults, only if:

• their condition is refractory to standard active treatments and rescue therapies or they have severe disease and a high risk of bleeding that needs frequent courses of rescue therapies.

Eltrombopag is recommended only if the company provides it with the discount agreed in the patient access scheme.

For more details of the updated recommendation for Eltrombopag go to https://www.nice.org.uk/guidance/ta293